Description

---

Preface.- Foreword.- Screening.- New Diagnostic Approaches.- PET and Staging Minimally Invasive (EBUS).- Innovative Approaches in Early NSCLC.- Minimally Invasive Surgery for Early NSCLC.- Stereotaxic Radiotherapy in Localized Cancer.- How to Personalize Perioperative Chemotherapy in Early Cancer ?.- New Approaches in Locally Advanced NSCLC.- Advances in Radiotherapy for Locally Advanced NSCLC.- Advances in Systemic Treatment for Locally Advanced NSCLC.- Surgery of Advanced Tumors.- New Approaches in Stage IV NSCLC.- How to Personalize Chemotherapy in Stage IV NSCLC?.- Supportive Care.- Molecular Subgroups.- Strategies in EGFR Mutated NSCLC Patients.- Strategies in ALK Rearranged NSCLC patients.- Strategies in KRAS mutated NSCLC Patients.- Strategies in Patients with Other Molecular Alterations.- New Approaches in Immunotherapy.- Management of Particular Cases.- Oligometastasis.- Bone Metastasis.- Brain Metastasis.

About the Author

---

Solange Peters, MD-PhD, PD-MER, is in charge of the thoracic malignancies program in the Department of Oncology of the University of Lausanne and active in building a translational program in collaboration with the molecular oncology laboratory directed by Prof. D. Hanahan and Prof. E. Meylan as well as the Ludwig Institute. Her main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also heavily involved and interested in developing multimodality trials for locally advanced NSCLC. She is co-chair of the Swiss lung cancer research group (SAKK) and Scientific Coordinator as well as Chair of the Informatics Committee of the European Thoracic Oncology Platform (ETOP). She has been elected the Swiss national representative of ESMO in 2013. Dr Benjamin Besse is a cancer specialist, Head of the Thoracic Oncology Unit at the Institut Gustave Roussy in France. His main research interests are application of molecular abnormalities to personalize treatment, phase I trials in thoracic tumors and thymic tumors. He has been the main Investigator of more than 30 phase I and phase II trials in the past 5 years. He coordinates the French network for thymic malignancies. He is associate editor of European Respiratory Journal. He was the coordinating author for the ESMO Guidelines Working Group on Non-Small Cell Lung Cancer (NSCLC) and is Chair of the systemic treatment part of the 2013 ESMO Consensus Conference on Lung Cancer. He is member of the administrative board of the French Intergroup for Thoracic Oncology (IFCT) and Member of ASCO, ESMO and IASLC.